AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00387868 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Concurrent Radiotherapy
Description: Preoperative External Beam Radiotherapy
Study NCT00306228 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postfibrinolysis percutaneous coronary intervention
Description: implantation of a paclitaxel eluting-stent with infusion of tirofiban 120 minutes after fibrinolysis
Study NCT00298233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir is a sialic acid analogue that potently and specifically inhibits the viral neuraminidases by competitively and reversibly interacting with the active enzyme site of influenza A and B viruses. Oseltamivir will be administered orally in standard formulations (capsules for adults and children at least 15 years of age; suspension for children younger than 15 years).
Study NCT02859194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Veno-veno-arterial ECMO
Study NCT01333475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206 + AZD6244
Description: MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.
Study NCT00435825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 90 or 180 micrograms subcutaneous weekly for 24 weeks or 48 weeks.
Study NCT04196582 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of LMA Gastro Airway® and Gastro-Laryngeal Tube in patients who will undergo biliopancreatic procedures.
Description: comparing efficiency and complications of second generation airway devices which can use for gastrointestinally procedures
Study NCT00350194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega-3 fatty acids
Description: Total of 1.8 grams of EPA +DHA in the form of fish oil capsules (3/day)
Study NCT02258633 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive interview and tailored family centered seatbelt safety intervention
Study NCT01136837 — intervention group
Intervention type: OTHER
Intervention: primary pcı
Study NCT02913651 — intervention group
Intervention type: DEVICE
Intervention: Polysomnography
Description: The polysomnography, for both groups, was performed accordance with standard practice
Study NCT02780999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whale orthosis
Description: Participants will be teach how to use the Whale orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain
Study NCT02780999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colditz orthosis
Description: Participants will be teach how to use the Colditz orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain.
Study NCT03923816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conservative fluid strategy: 12 mL/kg/h of Lactated Ringer (LR).&Restrictive fluid strategy:6 mL/kg/h of Lactated Ringer (LR).
Description: comparison of two intraoperative fluid strategies upon hepatic outcome in hepatobiliary surgery
Study NCT02996448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDV-3A
Description: A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.
Study NCT02015299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: one tablet linagliptin 5 mg/day for 26 weeks
Study NCT02015299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet matching placebo/day for 26 weeks
Study NCT02745379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BFPSCs+ DFDBA+ PRF
Study NCT02745379 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DFDBA + PRF
Study NCT01272934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium
Description: Topical gel 1%-4 times daily
Study NCT01272934 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical gel-4 times daily
Study NCT01681693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Subjects will be given an oral dose of metformin once per day for two days.
Study NCT00911365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous mesenchymal stem cells
Description: 4\*107 stem cell (100ml) Intra arterial infusion/ one time, then 4\*107 stem cell(100ml)Intravenous infusion 3 times/monthly~-> Total four times
Study NCT00911365 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: saline
Study NCT00803634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevidipine
Description: Clevidipine was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative IV antihypertensive agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Patients who received an alternative antihypertensive agent along with the study drug were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered approximately 1 hour prior to the termination of clevidipine with study drug down-titrated or terminated in order to maintain the desired blood pressure level.
Study NCT00803634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care IV antihypertensive
Description: SOC IV antihypertensive agent will be administered for a minimum of 30 min and, if medically warranted, may continue beyond 96 hours at the investigator's discretion. As with clevidipine, the SOC agent was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Higher dose titration rates were required to be attempted prior to making the decision to switch to or add on an alternative antihypertensive agent(s). Patients who received an alternative antihypertensive agent with SOC were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered per institutional practice.
Study NCT03818217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coach Pepper group
Description: Robot Pepper's height is 1.20 meters and it weighs 28 kilograms. Pepper's operation time is about 12 hours.~Pepper will be called as Coach Pepper because s/he is virtually connected via web interfaces with a theratainment app including cognitive and physical training .
Study NCT03818217 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tablet group
Description: The Tablet provides a theratainment app including cognitive and physical training.
Study NCT01175226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTA798
Description: BTA798 twice daily
Study NCT01175226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily
Study NCT00733265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6140
Description: single oral dose
Study NCT00976313 — intervention group
Intervention type: PROCEDURE
Intervention: Assessment of urinary micturition after thoracotomy
Description: Post residual urine volume and voided volume will be assessed with Bladder Scan™ BVI 6100 (Bladder scan, Bothell, WA, USA) will be performed the day before surgery and on day 2 after surgery, with epidural analgesia within segments T2-4 to T10 21,22. Bladder sensitivity will be assessed at strong desire to void. On day 2 the bladder will be filled through the transurethral catheter till the patient signalised a strong desire to void, then the catheter will be removed and spontaneous micturition will be attempted. Voided volume and post void residual will be assessed.
Study NCT00861341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 81 mg
Study NCT00861341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 30mg Pioglitazone x1
Study NCT01747759 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Kruskal-Wallis and qualitative parameters
Study NCT00141440 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mechanical ventilation
Description: evaluated the effect of two different cycling off criteria on breathing pattern, respiratory effort, and gas exchange in patients with chronic obstructive pulmonary disease
Study NCT03779386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: music during labor and delivery
Study NCT02268591 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Stimulator
Description: A non invasive brain stimulation which delivers low amplitude current through scalp electrodes by a Transcranial Stimulator
Study NCT00976313 — intervention group
Intervention type: OTHER
Intervention: International Prostate Symptom Score
Description: International Prostate Symptom Score (IPSS) for assessment of lower urinary tract symptoms (LUTS) preoperatively
Study NCT00634192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tobramycin
Description: 1x300mg/d inhaled
Study NCT00634192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tobramycin
Description: 2x300mg/d inhaled
Study NCT03344991 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardboard Cot Care
Description: When ready to be weaned from radiant warmer, infant will be placed in a reflective film-lined cot for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found \< 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
Study NCT04101084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Rocking sessions in a safe rocking chair for 2 hours daily for six weeks
Study NCT00800722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin Treatment of Port Wine Stain
Description: Treatment of Port Wine Stain
Study NCT02391922 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: First aid instructions by mobile phone
Study NCT06701695 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periarticular Injection (PAI)
Description: Patients in the periarticular injection group were administered a 100 mL periarticular solution comprising 200 mg of bupivacaine (40 mL), 60 mg of ketorolac (2 mL), 8 mg of dexamethasone (2 mL), 2 mg of 1:1000 epinephrine (2 mL), and standard saline solution (54 mL). This solution was prepared in two 50 mL syringes. The first syringe containing 50 mL of the cocktail was injected into the capsule and gluteal muscles prior to femoral stem insertion. Following joint capsule closure, the second syringe containing 50 mL of the periarticular injection cocktail was infiltrated into the fascia lata muscle, subcutaneous tissue, and wound layers.
Study NCT06701695 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control (Standard treatment)
Description: The control group received the conventional treatment protocol.
Study NCT06701695 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control (Standard treatment)
Description: The control group received the conventional treatment protocol.
Study NCT06702254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Psychological manualized treatment with CBT and ACT
Description: The intervention is brief and centered around four therapeutic sessions that can be extended or shortened depending on how long patients are hospitalized. Core techniques from CBT and ACT are included in the manual and consists of behavioral activation and values and unhelpful thoughts. Nursing staff on these wards have received training in the manual parallel with supervision which is not given in the treatment as usual wards. The wards that have not received the intervention will be offered this at the end of their TAU period.
Study NCT06702254 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: This treatment as usual can consist of medication, brief talks, leisure activity on the wards.
Study NCT03914937 — intervention group
Intervention type: OTHER
Intervention: Virtual reality
Description: A virtual reality device will be worn over the eyes that allows the patient to feel that they are at a quiet seaside beach.
Study NCT03914937 — intervention group
Intervention type: OTHER
Intervention: Music
Description: Music of the patient's choice will be played
Study NCT04519203 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPI
Description: Either standard monitoring alone or added with SPI
Study NCT04519203 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Standard monitoring alone
Study NCT01284231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-565
Description: MEDI-565 will be administered by IV infusion
Study NCT01284231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-565
Description: 20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
Study NCT01284231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-565
Description: 20 Subjects with refractory Gastroesophageal cancer to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
Study NCT04365842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital exercise group
Description: Hand Rehabilitation Program: Developed hand exercise smartphone app which include: Self-assessment, (b) self-monitoring (c) exercises types/frequency/ diary, (d) patient education, (e) behavioral change and encouragement (f) exercise adherence Sample exercises~1. Hand and finger movements: 6-8 repetitions, according to the diagnosis of the patient~2. Strengthening exercises of hand and finger muscles~3. Exercises to increase grip and pinch strength~4. Exercises to increase tendon swing and pull angle
Study NCT04365842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Home Hand Therapy
Description: Hand rehabilitation home program will be given to the through the telephone messages with brochures.~1. Hand and finger movements: 6-8 repetitions, according to the diagnosis of the patient~2. Strengthening exercises of hand and finger muscles~3. Exercises to increase grip and pinch strength~4. Exercises to increase tendon swing and pull angle
Study NCT03519360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UFR-restricted dialysis
Description: UFR's are limited to a maximum of 10 mL/kg/hr for the duration of the session. In order to prevent progressive volume overload and the need for additional hemodialysis sessions to manage volume gains in this scenario, subjects will crossover weekly between the restricted and unrestricted UFR interventions.
Study NCT03519360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UFR-unrestricted dialysis
Description: UFR's will be unlimited and prescribed according to the standard of care.
Study NCT03441958 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ECT-001 (UM171) expanded cord blood
Description: ECT-001 expanded cord-blood will be produced and infused on site
Study NCT03891979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given for two doses every 3 weeks starting on day 8 (ie days 8 and 29). Antibiotics will continue throughout the entire four week pre-operative period.~Ciprofloxacin 500mg PO BID days 1-29; Metronidazole 500mg PO TID days 1-29; Pembrolizumab 200mg IV days 8 and 29.
Study NCT03891979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500mg PO BID days 1-29
Description: Antibiotics will continue throughout the entire four week pre-operative period.
Study NCT03891979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 500mg PO TID days 1-29
Description: Antibiotics will continue throughout the entire four week pre-operative period.
Study NCT00079963 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 1000 mg/day
Study NCT00079963 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: 800 IU/day
Study NCT00079963 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03344991 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Open Crib
Description: When ready to be weaned from radiant warmer, infant will be placed in a standard of care open crib for the duration of hospitalization. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after placement in cot, and every 24 hours thereafter until discharge. If temperatures found \< 36.0 at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including early and exclusive breastfeeding, appropriate bundling, and Kangaroo Mother Care as continuously as possible.
Study NCT03695042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Training with Exercise
Description: The addition of BFR training to an exercise program prescribed for a patient participating in physical therapy for concussion treatment. BFR training partially occludes blood flow to extremities during exercise. This allows one to exercise at lower loads and still gain benefits similar to exercise at higher loads
Study NCT02278601 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: epidural delivery system
Description: epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
Study NCT02278601 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: epidural delivery system
Description: epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
Study NCT02278601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
Study NCT02278601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
Study NCT02278601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
Study NCT02278601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
Study NCT02908269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative
Description: 0.5 mL, Intramuscular
Study NCT03454334 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: multifocal intraocular lens IOLs
Description: clinical outcome of different multifocal intraocular lenses (IOLs) in patients with presbyopia or cataracts
Study NCT02908269 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High-Dose, vaccine, 2016-2017 formulation
Description: 0.5 mL, Intramuscular
Study NCT04057495 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: further fasting
Description: 2 hours of fasting
Study NCT04057495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: white bread consumption
Description: 113 grams of white bread consumption
Study NCT04057495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mango consumption
Description: 330 grams of mango consumption
Study NCT00510666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline infusion adjunct to morphine PCA pump
Study NCT00510666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol tartrate
Description: Butorphanol was delivered at a continuous infusion manner adjunct to morphine PCA pump
Study NCT00510666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride
Description: 100mg tramadol was used preemptively to morphine PCA pump
Study NCT00510666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Preemptive saline as a control group to tramadol one